Therapeutic Class
Novartis adding cystinosis gene therapy candidate from AvroBio
Therapeutic ClassNovartis adding cystinosis gene therapy candidate from AvroBioNovartis adding cystinosis gene therapy candidate from AvroBio
Novartis will pay $87.5 million in cash to add the Phase I/II HSC gene therapy program to its advanced therapy pipeline.